81 related articles for article (PubMed ID: 1905850)
1. Fibrinogen does not protect von Willebrand factor against proteolysis by human cathepsin G.
Jeleńska M; Kopeć M; Sopata I; Vigh Z; Scharrer I; Breddin K
Thromb Res; 1991 Feb; 61(4):433-40. PubMed ID: 1905850
[TBL] [Abstract][Full Text] [Related]
2. Effects of human elastase on von Willebrand factor in highly purified factor VIII concentrate and in cryoprecipitate.
Jeleńska M; Bykowska W; Kopeć M; Vigh Z; Scharrer I; Breddin K
Thromb Res; 1990 Jul; 59(2):295-307. PubMed ID: 2122538
[TBL] [Abstract][Full Text] [Related]
3. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
Cattaneo M; Simoni L; Gringeri A; Mannucci PM
Br J Haematol; 1994 Feb; 86(2):333-7. PubMed ID: 8199023
[TBL] [Abstract][Full Text] [Related]
4. Proteolysis of subendothelial adhesive glycoproteins (fibronectin, thrombospondin, and von Willebrand factor) by plasmin, leukocyte cathepsin G, and elastase.
Bonnefoy A; Legrand C
Thromb Res; 2000 May; 98(4):323-32. PubMed ID: 10822079
[TBL] [Abstract][Full Text] [Related]
5. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma.
Tsai HM; Sussman II; Nagel RL
Blood; 1994 Apr; 83(8):2171-9. PubMed ID: 8161783
[TBL] [Abstract][Full Text] [Related]
6. The role of fibronectin in factor VIII/von Willebrand factor cryoprecipitation.
Mazurier C; Samor B; Deromeuf C; Goudemand M
Thromb Res; 1985 Mar; 37(6):651-8. PubMed ID: 3922084
[TBL] [Abstract][Full Text] [Related]
7. Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain.
Hamer RJ; Koedam JA; Beeser-Visser NH; Bertina RM; Van Mourik JA; Sixma JJ
Eur J Biochem; 1987 Jul; 166(1):37-43. PubMed ID: 3109914
[TBL] [Abstract][Full Text] [Related]
8. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
9. Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma.
Aznar JA; Molina R; Montoro JM
Transfusion; 1999 Jul; 39(7):748-50. PubMed ID: 10413283
[TBL] [Abstract][Full Text] [Related]
10. DDAVP, cryoprecipitate, and highly 'purified' factor VIII concentrate in uremia.
Juhl A
Nephron; 1986; 43(4):305-6. PubMed ID: 3090461
[No Abstract] [Full Text] [Related]
11. Interaction between VWF and FVIII in treating VWD.
Miesbach W; Berntorp E
Eur J Haematol; 2015 Nov; 95(5):449-54. PubMed ID: 25605439
[TBL] [Abstract][Full Text] [Related]
12. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
[TBL] [Abstract][Full Text] [Related]
13. Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely.
Layet S; Girma JP; Obert B; Peynaud-Debayle E; Bihoreau N; Meyer D
Biochem J; 1992 Feb; 282 ( Pt 1)(Pt 1):129-37. PubMed ID: 1531749
[TBL] [Abstract][Full Text] [Related]
14. Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III.
Houdijk WP; Sakariassen KS; Nievelstein PF; Sixma JJ
J Clin Invest; 1985 Feb; 75(2):531-40. PubMed ID: 3919060
[TBL] [Abstract][Full Text] [Related]
15. A new method measuring the interaction between von Willebrand factor and coagulation factor VIII.
Karlman M; Holmström M; Wiman B
Thromb Res; 2011 Jan; 127(1):47-50. PubMed ID: 21094987
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil Protease Cleavage of Von Willebrand Factor in Glomeruli - An Anti-thrombotic Mechanism in the Kidney.
Tati R; Kristoffersson AC; Manea Hedström M; Mörgelin M; Wieslander J; van Kooten C; Karpman D
EBioMedicine; 2017 Feb; 16():302-311. PubMed ID: 28139439
[TBL] [Abstract][Full Text] [Related]
17. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII.
Fischer BE; Kramer G; Mitterer A; Grillberger L; Reiter M; Mundt W; Dorner F; Eibl J
Thromb Res; 1996 Oct; 84(1):55-66. PubMed ID: 8885147
[TBL] [Abstract][Full Text] [Related]
18. Reactivity of small molecular forms of human factor VIII/von Willebrand factor with botrocetin and anti-factor VIII-coated latex particles.
Furlan M; Perret BA; Beck EA
Thromb Haemost; 1985 Aug; 54(2):463-5. PubMed ID: 3936216
[TBL] [Abstract][Full Text] [Related]
19. Elevated fibrinogen, von Willebrand factor, and Factor VIII confer resistance to dilutional coagulopathy and activated protein C in normal pregnant women.
Tanaka KA; Bharadwaj S; Hasan S; Judd M; Abuelkasem E; Henderson RA; Chow JH; Williams B; Mazzeffi MA; Crimmins SD; Malinow AM
Br J Anaesth; 2019 Jun; 122(6):751-759. PubMed ID: 30916034
[TBL] [Abstract][Full Text] [Related]
20. Laboratory Testing for von Willebrand Factor: Factor VIII Binding (for 2N VWD).
Mohammed S; Favaloro EJ
Methods Mol Biol; 2017; 1646():461-472. PubMed ID: 28804848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
